| 前收盘价格 | 18.00 |
| 收盘价格 | 17.78 |
| 成交量 | 189,912 |
| 平均成交量 (3个月) | 1,251,146 |
| 市值 | 2,093,375,360 |
| 价格/销量 (P/S) | 612.75 |
| 股市价格/股市净资产 (P/B) | 5.24 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2026 |
| 营业利益率 (TTM) | -1,525.50% |
| 稀释每股收益 (EPS TTM) | -3.01 |
| 季度收入增长率 (YOY) | 184.40% |
| 总债务/股东权益 (D/E MRQ) | 1.55% |
| 流动比率 (MRQ) | 10.49 |
| 营业现金流 (OCF TTM) | -152.68 M |
| 杠杆自由现金流 (LFCF TTM) | -117.16 M |
| 资产报酬率 (ROA TTM) | -33.54% |
| 股东权益报酬率 (ROE TTM) | -69.21% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Immunome, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | 1.17 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 11.48% |
| 机构持股比例 | 83.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 4,911,590 |
| Primecap Management Co/Ca/ | 30 Jun 2026 | 4,581,431 |
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 3,613,799 |
| Silverarc Capital Management, Llc | 30 Jun 2026 | 2,017,009 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合